Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
20023.2k citationsBrian G. Feagan, Jean‐Frédéric Colombel et al.profile →
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
20052.9k citationsPaul Rutgeerts, William J. Sandborn et al.New England Journal of Medicineprofile →
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
19972.5k citationsStephen B. Hanauer, Paul Rutgeerts et al.New England Journal of Medicineprofile →
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
20102.3k citationsJean‐Frédéric Colombel, William J. Sandborn et al.New England Journal of Medicineprofile →
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
20132.0k citationsBrian G. Feagan, Paul Rutgeerts et al.New England Journal of Medicineprofile →
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
20132.0k citationsWilliam J. Sandborn, Brian G. Feagan et al.New England Journal of Medicineprofile →
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
20061.7k citationsWilliam J. Sandborn, Paul Rutgeerts et al.Gastroenterologyprofile →
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
20041.6k citationsBruce E. Sands, Brian G. Feagan et al.New England Journal of Medicineprofile →
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
20031.6k citationsFilip Baert, Maja Noman et al.New England Journal of Medicineprofile →
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
20061.3k citationsWilliam J. Sandborn, Paul Rutgeerts et al.Gastroenterologyprofile →
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006903 citationsGeert D’Haens, William J. Sandborn et al.Gastroenterologyprofile →
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
1999875 citationsPaul Rutgeerts, Geert D’Haens et al.Gastroenterologyprofile →
Certolizumab Pegol for the Treatment of Crohn's Disease
2007863 citationsWilliam J. Sandborn, Brian G. Feagan et al.New England Journal of Medicineprofile →
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012838 citationsWilliam J. Sandborn, Bruce E. Sands et al.New England Journal of Medicineprofile →
Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test
1993791 citationsYvo Ghoos, Bart Maes et al.Gastroenterologyprofile →
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
2005789 citationsGert Van Assche, Séverine Vermeire et al.New England Journal of Medicineprofile →
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
2007740 citationsWilliam J. Sandborn, Paul Rutgeerts et al.profile →
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
2004737 citationsPaul Rutgeerts, Brian G. Feagan et al.Gastroenterologyprofile →
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013701 citationsWilliam J. Sandborn, Brian G. Feagan et al.Gastroenterologyprofile →
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
2011693 citationsJean‐Frédéric Colombel, Paul Rutgeerts et al.Gastroenterologyprofile →
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
2005688 citationsWilliam J. Sandborn, Jean‐Frédéric Colombel et al.New England Journal of Medicineprofile →
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
2013685 citationsRemo Panaccione, Subrata Ghosh et al.Gastroenterologyprofile →
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
2009648 citationsFilip Baert, Gert Van Assche et al.Gastroenterologyprofile →
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
2015636 citationsNiels Vande Casteele, Marc Ferrante et al.Gastroenterologyprofile →
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
2012628 citationsGeert D’Haens, Marc Ferrante et al.Inflammatory Bowel Diseasesprofile →
Natalizumab for Active Crohn's Disease
2003615 citationsSubrata Ghosh, Paul Rutgeerts et al.New England Journal of Medicineprofile →
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008592 citationsWilliam J. Sandborn, Brian G. Feagan et al.Gastroenterologyprofile →
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
1999585 citationsGeert D’Haens, Filip Baert et al.Gastroenterologyprofile →
The safety of vedolizumab for ulcerative colitis and Crohn's disease
2016563 citationsJean‐Frédéric Colombel, Bruce E. Sands et al.Gutprofile →
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
2013549 citationsWilliam J. Sandborn, Brian G. Feagan et al.Gastroenterologyprofile →
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
2009533 citationsMarc Ferrante, Maja Noman et al.Inflammatory Bowel Diseasesprofile →
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
2014531 citationsBruce E. Sands, Brian G. Feagan et al.Gastroenterologyprofile →
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease
2002515 citationsWilliam J. Sandborn, Brian G. Feagan et al.Gastroenterologyprofile →
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
2012460 citationsPaul Rutgeerts, Gert Van Assche et al.Gastroenterologyprofile →
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
2013363 citationsLaurent Peyrin‐Biroulet, Walter Reinisch et al.Gutprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Paul Rutgeerts
Since
Specialization
Citations
This map shows the geographic impact of Paul Rutgeerts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Rutgeerts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Rutgeerts more than expected).
This network shows the impact of papers produced by Paul Rutgeerts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Rutgeerts. The network helps show where Paul Rutgeerts may publish in the future.
Co-authorship network of co-authors of Paul Rutgeerts
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Rutgeerts.
A scholar is included among the top collaborators of Paul Rutgeerts based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Paul Rutgeerts. Paul Rutgeerts is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851.563 indexed citations breakdown →
Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 369(8). 711–721.2011 indexed citations breakdown →
9.
Peyrin‐Biroulet, Laurent, Walter Reinisch, Jean–Frédéric Colombel, et al.. (2013). Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 63(1). 88–95.363 indexed citations breakdown →
Cloetens, Lieselotte, Vicky De Preter, Katrien Swennen, et al.. (2006). The effect of two different types of arabinoxylanoligosaccharides on the level of human faecal bifidobacteria determined using real-time PCR. annales de biologie animale biochimie biophysique.1 indexed citations
14.
Hlavatý, Tibor, Philippe Persoons, Séverine Vermeire, et al.. (2005). IBDQ score is a sensitive instrument to assess short-term changes in disease related quality of life in patients with luminal Crohn's disease. Gastroenterology. 128(4).
Vermeire, Séverine, Jack Satsangi, Marc Peeters, et al.. (1999). Fine mapping a susceptibility locus on the X chromosome in the Belgian population in inflammatory bowel disease (IBD). Gastroenterology. 116(4).3 indexed citations
17.
Löfberg, Robert, Ragnar Befrits, Per Karlén, et al.. (1996). Colorectal cancer in colonic Crohn's disease-High frequency of DNA-aneuploidy. Gut.1 indexed citations
18.
D’Haens, G, Alain Verstraete, Filip Baert, et al.. (1996). Osteoblast function is suppressed by oral methylprednisolone but not by budesonide CIR in active ileocolonic Crohn's disease. Gastroenterology. 110(4).1 indexed citations
19.
Maes, Bart, Yvo Ghoos, Benny Geypens, Paul Rutgeerts, & Martin Hiele. (1994). The combined 13c-glycine/14c-octanoic acid breath test to monitor gastric-emptying rate of liquids and solids simultaneously. Gastroenterology. 106(4).1 indexed citations
20.
Ectors, Nadine, et al.. (1992). Malabsorption and motor dysfunction in small bowel amyloidosis - report of two cases and review of the literature. European Journal of Gastroenterology & Hepatology. 4(5). 361–366.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.